A New Study Says GLP-1 Drugs Cut Long-Term Employee Sick Leave by 17% — Here's the Science Behind That Number
A new economic study links GLP-1 medications to a 17% drop in worker sick leave. The biology explains why.
Now I have everything I need. Let me write the article.
A new study says GLP-1 drugs could cut long-term employee sick leave by 17%. That's not a rounding error — that's a number big enough to make HR departments and insurers pay very close attention.
What the Study Actually Found
CBS News reported that a new economic study found GLP-1 drugs are linked to a 17% drop in worker sick leave. The Washington Post and The Independent both covered the same findings this week: employees on GLP-1 medications are taking fewer sick days — specifically fewer long-term sick days, the kind that drag on for weeks and cost employers the most.
The study frames this as an economic argument for covering GLP-1s. The logic is straightforward: treat the underlying condition (obesity), and the downstream health problems that pull people out of work — joint pain, cardiovascular events, diabetes complications — become less likely.
Why Obesity and Sick Leave Are Already Linked
This connection isn't new. A 2008 study published in the Journal of Occupational and Environmental Medicine found that obesity is significantly associated with reduced workplace productivity — a concept researchers call "presenteeism," where you show up but can't perform. That study found the impact on productivity grew alongside BMI.
MedlinePlus (NIH) describes obesity as a disease — not a lifestyle choice — that raises the risk of type 2 diabetes, heart disease, kidney disease, and certain cancers. Every one of those conditions can pull someone off the job for days, weeks, or months at a time. When you treat obesity, you're not just changing a number on a scale. You're potentially reducing the cascade of illness that follows it.
What GLP-1 Drugs Are Actually Approved to Do
It's worth grounding this in what the drugs are officially cleared for. According to the FDA's label for Wegovy (semaglutide), the drug is indicated not just for weight reduction, but specifically to reduce the risk of major adverse cardiovascular events — including heart attack and stroke — in adults with established cardiovascular disease and obesity or overweight.
That cardiovascular indication matters here. Heart events are one of the leading causes of long-term sick leave and permanent disability. If GLP-1s are reducing those events, the sick-leave connection makes biological sense.
A 2024 analysis of the SELECT trial published in The Lancet examined semaglutide's cardiovascular outcomes specifically in patients with obesity and heart failure, finding meaningful benefits in that high-risk population. A pooled analysis across the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials, also published in The Lancet, reinforced semaglutide's positive signal in patients with heart failure and preserved ejection fraction. Fewer cardiac events = fewer hospitalizations = fewer extended absences from work.
The Cost-Coverage Argument Just Got Louder
For years, employers and insurers have resisted covering GLP-1s because of their price tag. That calculus is starting to shift. A 2026 cost-effectiveness study in the Journal of Medical Economics compared tirzepatide and semaglutide head-to-head in U.S. patients with obesity, adding to the growing body of evidence that these drugs can deliver economic value — not just clinical value.
The new sick-leave data adds a layer that actuaries can actually model: if covering GLP-1s reduces long-term disability claims and extended sick leave, the math on coverage starts to look different. The Independent noted this week that "the workforce runs on weight-loss drugs" — a headline that would have sounded absurd five years ago and today sounds almost obvious.
What This Means for You
- If your employer doesn't cover GLP-1s, this growing body of economic evidence is the argument your HR department or benefits team is most likely to respond to — it's not just about your health, it's about their bottom line.
- The sick-leave benefit isn't magic — it appears to flow from treating obesity-related conditions like cardiovascular disease and metabolic dysfunction, not from the drug doing something directly to your attendance record.
- Tirzepatide and semaglutide are the two most-studied drugs in this space right now, with multiple large trials backing their health-outcome data — but talk to your prescriber about which, if either, is right for your specific situation.
Not medical advice. Talk to your prescriber about your situation.
